The OncotypeDX signature, based on 21 genes, was originally used to stratify estrogen receptor (ER) positive, lymph node (LN) negative, HER-2 neu normal breast cancer into recurrence risk categories [10]. This evidence concerns the gene ESR1 and breast carcinoma.